Travere Therapeutics, Inc.
TVTX
$17.92
$0.130.73%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -169.06M | -226.71M | -321.55M | -351.45M | -145.91M |
| Total Depreciation and Amortization | 50.15M | 46.48M | 43.56M | 40.95M | 41.19M |
| Total Amortization of Deferred Charges | 1.73M | 1.73M | 1.73M | 1.72M | 1.72M |
| Total Other Non-Cash Items | 30.41M | 101.61M | 101.81M | 99.88M | -124.38M |
| Change in Net Operating Assets | -28.67M | -83.77M | -63.02M | -63.32M | -61.48M |
| Cash from Operations | -115.44M | -160.66M | -237.48M | -272.23M | -288.86M |
| Capital Expenditure | -153.00K | 0.00 | 0.00 | 561.00K | 551.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 12.11M | 35.72M | 99.33M | 162.12M | 249.33M |
| Cash from Investing | 11.96M | 35.72M | 99.33M | 162.68M | 249.88M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 146.46M | 145.77M | 141.52M | 2.79M | 2.37M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -2.10M | -2.10M | -2.10M | -2.36M | -2.62M |
| Cash from Financing | 144.36M | 143.67M | 139.42M | 427.00K | -253.00K |
| Foreign Exchange rate Adjustments | 1.99M | -72.00K | -913.00K | 1.28M | 649.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 42.86M | 18.65M | 359.00K | -107.84M | -38.58M |